Drug intelligence / Profile preview

VBD00006

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VBD00006 is a vaccine candidate developed for preventing respiratory infections in older adults, specifically targeting **Respiratory Syncytial Virus (RSV)**, **Human Metapneumovirus (hMPV)**, and **Parainfluenza Virus Type 3 (PIV3)**. It is being evaluated in a **Phase 1, dose-escalation, randomized, active-controlled, modified double-blind, parallel-group, multi-arm study** in adults aged 60 years and older, assessing safety through adverse events, serious adverse events, and immunogenicity via serum neutralizing antibody titers against RSV A/B, hMPV A, and PIV3.[1][4][7]

Beyond the preview

Go deeper on VBD00006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VBD00006.

Explore the full profile